BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Embryo, Autoimmunity, Prozac, rs2300478, VEGFA, glucose metabolic process, Arthritis)
Bookmark Forward

QuickView for EZH2 (gene)


Body Atlas

Most Correlated Tissues

  1. Hematopoietic stem cell of bone marrow
  2. Granulocyte-macrophage progenitor cell of bone marrow
  3. T Lymphocyte (regulatory) of peripheral blood
  4. Dendritic (plasmacytoid) cell
  5. Testes
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Toxoplasmosis
  2. Disease due to Orthopoxvirus
  3. Injury of lung
  4. Listeriosis
  5. Disease due to Lentivirus
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. Herceptin
  2. Nonoxynol-9
  3. Adenovirus E1A Proteins
  4. PD 0332991
  5. hen egg lysozyme
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. Mir34c
  2. L1TD1
  3. PXDN
  4. ZIC3
  5. EZH2
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Targeting EZH2 as cancer therapy.
  2. A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.
  3. Tumor-suppressive function of EZH2 is through inhibiting glutaminase.
  4. The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma.
  5. EZH2 and Endometrial Cancer Development: Insights from a Mouse Model.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia
  2. A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negativ…
  3. Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With…
  4. EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
  5. Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Explore Clinical Trials Results
  • Copyright © 2022 Illumina Inc. All rights reserved.